Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 1-Year Low – Time to Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s stock price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $28.97 and last traded at $29.18, with a volume of 46245 shares traded. The stock had previously closed at $29.70.

Analysts Set New Price Targets

Several brokerages have recently weighed in on COLL. HC Wainwright raised their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. Piper Sandler reiterated a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.60.

Collegium Pharmaceutical Trading Down 0.3 %

The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The firm has a 50-day moving average of $32.30 and a two-hundred day moving average of $34.30. The firm has a market capitalization of $937.19 million, a P/E ratio of 12.53 and a beta of 0.80.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. nVerses Capital LLC raised its stake in Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,600 shares during the last quarter. GAMMA Investing LLC grew its holdings in Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 792 shares during the period. CWM LLC increased its stake in Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after purchasing an additional 736 shares in the last quarter. TD Private Client Wealth LLC raised its holdings in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares during the period. Finally, Virtus Fund Advisers LLC bought a new position in shares of Collegium Pharmaceutical during the 3rd quarter worth about $72,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.